§ Mr. Burstow
To ask the Secretary of State for Health if he will specify the unanswered questions about the appropriate use of beta-interferon referred to in his answer of 17 November,Official Report, columns 566–67, on which his Department is commissioning new research. 
§ Mr. Hutton
I refer the hon. Member to the reply I gave my hon. Friend the Member for Birmingham, Erdington (Mr. Corbett) on 26 January 1999,Official Report, column 211.
A range of research questions are under consideration, broadly relating to the long-term clinical effectiveness of beta-interferon and its cost effectiveness relative to other treatments for multiple sclerosis.